Table 6.
Effects trientine on cardiac structure/hypertrophy in human and animal studies.
| Study | Type of Model/Subjects | Trientine (TETA) (Dose and Duration) |
Findings | Reference |
|---|---|---|---|---|
| Animal | STZ-induced diabetic cardiomyopathy in rats |
20 mg/day in drinking water for 8 weeks (post-treatment) (~68 mg/kg/day) | ↓ HW/BW | [38] |
| Animal | STZ-induced diabetic cardiomyopathy in rats |
8–11 mg/day in drinking water for 7 weeks (post-treatment) | ↓ HW/BW | [39] |
| Animal | STZ-induced diabetic cardiomyopathy in rats |
20 mg/day in drinking water for 8 weeks (post-treatment) | ↓ HW/BW | [42] |
| Animal | Ascending aortic constriction-induced cardiac hypertrophy in rats | 21.9 mg/kg twice daily orally for 6 weeks | ↓ cardiomyocyte size ↔ cardiac vimentin |
[15] |
| Animal | STZ-induced diabetic cardiomyopathy in rats |
20 mg/day in drinking water for 8 weeks (post-treatment) | ↔ HW/BW | [25] |
| Animal | Transverse aortic constriction- induced cardiac hypertrophy in rats |
21.9 and 87.6 mg/kg twice daily orally for 6 weeks | TETA (21.9 mg/kg/day): ↓ LVAWd ↓ LVPWd ↓ HW/TL ↓ cardiomyocyte size TETA (87.6 mg/kg/day): ↔ LVAWd ↔ LVPWd ↔ HW/BW ↔ cardiomyocyte size |
[14] |
| Animal | STZ-induced diabetic cardiomyopathy in rats |
20 mg/day in drinking water for 8 weeks (post-treatment) | ↓ LV mass/BW | [51] |
| Animal | STZ-induced diabetic cardiomyopathy in rats |
8–11 mg/day orally for 6 weeks | Improved myocardial structure | [80] |
| Animal | STZ-induced diabetic cardiomyopathy in rats |
30 mg/day in drinking water for 7 weeks (preventive) | ↔ HW/BW | [33] |
| Animal | STZ-induced diabetic cardiomyopathy in rats |
20 mg/day in drinking water for 8 weeks (post-treatment) | ↓ HW/BW | [34] |
| Human | Type 2 diabetic patients with LVH (n = 15) | 600 mg twice daily orally for 12 months | ↓ LVMbsa | [40] |
| Human | Patients with hypertrophic cardiomyopathy (n = 20) |
300 mg twice daily orally, increased after 1 week to 600 mg daily if tolerated for 6 months | ↔ LVMbsa | [23] |
BW, body weight; HW, heart weight; LVAWd, diastolic left anterior ventricular wall thickness; LV, left ventricle; LVH, left ventricular hypertrophy; LVMbsa, left ventricular mass per body surface area; LVPWd, diastolic left posterior ventricular wall thickness; STZ, streptozotocin; TL, tibial length; ↓, significant decrease; ↔, no difference.